In support of this hypothesis, we have reported resistance to IL-10’s anti-inflammatory action under hyperglycemic conditions in vitro (12, 13) and in individuals with type 2 diabetes (T2D) (12). The gene discussed is IL10; the disease is type 2 diabetes mellitus.